Recent experimental and genetic studies have implicated the role of programmed cell death
protein 1 (PD-1), programmed cell death protein-ligand 1 (PDL-1), and cytotoxic T …

Objective To compare the efficacy of abatacept to that of placebo for the treatment of giant cell
arteritis (GCA). Methods In this multicenter trial, patients with newly diagnosed or relapsing …

We conducted a large-scale genetic analysis on giant cell arteritis (GCA), a polygenic
immune-mediated vasculitis. A case-control cohort, comprising 1,651 case subjects with GCA and …

Objective To compare the efficacy of abatacept to that of placebo for the treatment of
Takayasu arteritis (TAK). Methods In this multicenter trial, patients with newly diagnosed or …

Objectives Evaluation of rituximab and glucocorticoids as therapy to induce remission after
relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients …

Objective To identify and validate, using computer‐driven methods, patterns of arterial disease
in Takayasu arteritis (TAK) and giant cell arteritis (GCA). Methods Patients with TAK or …

Objective Takayasu arteritis is a rare large vessel vasculitis with incompletely understood
etiology. This study was undertaken to perform the first unbiased genome‐wide association …

Objective Following induction of remission with rituximab in anti-neutrophil cytoplasmic
antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of …

Objective. The goal of the Outcome Measures in Rheumatology (OMERACT) 12 (2014)
equity working group was to determine whether and how comprehensibility of patient-reported …

Objective Takayasu's arteritis (TAK) is a clinically heterogenous disease. Patterns of clinical
presentation in TAK at diagnosis have not been well described, and a “triphasic pattern” of …